Combination of genetic and quantitative serological immune markers are associated with complicated XXXX behavior.

@entity1 @entity66 @entity146 @entity6820 @entity30
BACKGROUND: Treatment of @entity30 ( @entity30 ) with biologics may alter disease progression, leading to fewer @entity66 , but cost and adverse event profiles often limit their effective use. Tools identifying @entity1 at high risk of complications, who would benefit the most from biologics, would be valuable. Previous studies suggest that biomarkers may aid in determining the course of @entity30 . We aimed to determine if combined serologic immune responses and @entity6820 genetic markers are associated with @entity30 complications. METHODS: In this cross-sectional study, banked blood from well-characterized @entity30 @entity1 (n = 593; mean follow-up: 12 years) from tertiary and community centers was analyzed for six serological biomarkers (ASCA-IgA, ASCA-IgG, anti-OmpC, anti-CBir1, anti-I2, pANCA). In a @entity1 subset (n = 385), @entity6820 (SNP8, SNP12, SNP13) genotyping was performed. Complications included stricturing and penetrating @entity146 . A logistic regression model for the risk of complications over time was constructed and evaluated by cross-validation. RESULTS: For each serologic marker, complication rates were stratified by quartile. Complication frequency was significantly different across quartiles for each marker (P trend  <= 0.001). @entity1 with SNP13 @entity6820 risk alleles experienced increased complications versus @entity1 without @entity6820 mutations (P  <= 0.001). A calibration plot of modeled versus observed complication rates demonstrated good agreement (R = 0.973). Performance of the model integrating serologic and genetic markers was demonstrated by area under the receiver operating characteristic curve (AUC = 0.801; 95% confidence interval: 0.757-0.846). CONCLUSIONS: This model combining serologic and @entity6820 genetic markers may provide physicians with a tool to assess the probability of @entity1 developing a complication over the course of @entity30 .
